![Tord Labuda](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tord Labuda
Directeur Général chez
ALZINOVA AB
Profil
Tord Labuda is Chief Executive Officer at Alzinova AB since 2024 and Independent Director at NanoEcho AB since 2023.
Formerly, Dr. Labuda was Vice President & Global Head-Clinical Development at LEO Pharma A from 2008 to 2023.
Education includes a doctorate from the University of Lund.
Postes actifs de Tord Labuda
| Sociétés | Poste | Début |
|---|---|---|
| NANOECHO AB | Directeur/Membre du Conseil | 01/01/2023 |
| ALZINOVA AB | Directeur Général | 01/10/2024 |
Anciens postes connus de Tord Labuda
| Sociétés | Poste | Fin |
|---|---|---|
LEO Pharma A/S
 LEO Pharma A/S Medical/Nursing ServicesHealth Services Provides dermatology services | Corporate Officer/Principal | 01/01/2023 |
Formation de Tord Labuda
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
21
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
LEO Pharma A/S
LEO Pharma A/S Medical/Nursing ServicesHealth Services Provides dermatology services | Health Services |
University of Lund
 University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alzinova AB
 Alzinova AB Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provides treatment for Alzheimer’s disease | Health Technology |
Nanoecho AB
 Nanoecho AB Medical SpecialtiesHealth Technology Develops medical ultrasound imaging equipment to treat rectal cancer | Health Technology |
